Perspective Therapeutics Files 8-K
Ticker: CATX · Form: 8-K · Filed: Jan 24, 2025 · CIK: 728387
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Perspective Therapeutics filed an 8-K on Jan 24, 2025. Standard reporting.
AI Summary
Perspective Therapeutics, Inc. filed an 8-K on January 24, 2025, reporting on other events and financial statements. The company, formerly known as Isoray, Inc., is incorporated in Delaware and headquartered in Seattle, Washington.
Why It Matters
This filing provides an update on the company's corporate events and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating no immediate significant events or changes.
Key Numbers
- 001-33407 — SEC File Number (Identifies the company's filing with the SEC)
- 41-1458152 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Isoray, Inc. (company) — Former company name
- January 24, 2025 (date) — Date of report
- Seattle, Washington (location) — Company headquarters
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item, but the specific details of these events are not provided in the provided text snippet.
What is the SIC code for Perspective Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Perspective Therapeutics, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
When did Perspective Therapeutics, Inc. change its name from Isoray, Inc.?
The filing indicates a name change from Isoray, Inc. on December 31, 2018.
What is the fiscal year end for Perspective Therapeutics, Inc.?
The fiscal year end for Perspective Therapeutics, Inc. is December 31 (1231).
What is the business address of Perspective Therapeutics, Inc.?
The business address is 2401 Elliott Avenue, Suite 320, Seattle, WA 98121.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-01-24 07:26:49
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20250124.htm (8-K) — 44KB
- catx-ex99_1.htm (EX-99.1) — 53KB
- catx-ex99_2.htm (EX-99.2) — 34KB
- img236230851_0.jpg (GRAPHIC) — 22KB
- catx-ex99_2s1.jpg (GRAPHIC) — 158KB
- catx-ex99_2s2.jpg (GRAPHIC) — 695KB
- catx-ex99_2s3.jpg (GRAPHIC) — 329KB
- catx-ex99_2s4.jpg (GRAPHIC) — 304KB
- catx-ex99_2s5.jpg (GRAPHIC) — 308KB
- catx-ex99_2s6.jpg (GRAPHIC) — 340KB
- catx-ex99_2s7.jpg (GRAPHIC) — 133KB
- catx-ex99_2s8.jpg (GRAPHIC) — 362KB
- catx-ex99_2s9.jpg (GRAPHIC) — 355KB
- catx-ex99_2s10.jpg (GRAPHIC) — 212KB
- catx-ex99_2s11.jpg (GRAPHIC) — 209KB
- catx-ex99_2s12.jpg (GRAPHIC) — 393KB
- catx-ex99_2s13.jpg (GRAPHIC) — 363KB
- catx-ex99_2s14.jpg (GRAPHIC) — 163KB
- catx-ex99_2s15.jpg (GRAPHIC) — 409KB
- catx-ex99_2s16.jpg (GRAPHIC) — 184KB
- catx-ex99_2s17.jpg (GRAPHIC) — 247KB
- catx-ex99_2s18.jpg (GRAPHIC) — 229KB
- catx-ex99_2s19.jpg (GRAPHIC) — 249KB
- catx-ex99_2s20.jpg (GRAPHIC) — 268KB
- catx-ex99_2s21.jpg (GRAPHIC) — 252KB
- catx-ex99_2s22.jpg (GRAPHIC) — 313KB
- catx-ex99_2s23.jpg (GRAPHIC) — 367KB
- catx-ex99_2s24.jpg (GRAPHIC) — 101KB
- catx-ex99_2s25.jpg (GRAPHIC) — 369KB
- catx-ex99_2s26.jpg (GRAPHIC) — 106KB
- catx-ex99_2s27.jpg (GRAPHIC) — 88KB
- catx-ex99_2s28.jpg (GRAPHIC) — 266KB
- 0000950170-25-008603.txt ( ) — 10997KB
- catx-20250124.xsd (EX-101.SCH) — 25KB
- catx-20250124_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 24, 2025, Perspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing certain initial results from its Phase 1/2a study of [ 212 Pb]VMT--NET for the treatment and diagnosis of patients with somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs) that are being presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium taking place from January 23-25, 2025 in San Francisco, California. A copy of the press release is filed herewith as Exhibit 99.1, and a copy of the presentation is filed herewith as Exhibit 99.2, and each is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 24, 2025 . 99.2 Investor Presentation . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: January 24, 2025 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer